Login / Signup

Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma.

Weiwei JiaJianhui WuHongtao ZhangYan WuDaoning LiuZhen WangXiaopeng WangChengpeng LiChun-Yi Hao
Published in: Therapeutic advances in medical oncology (2024)
The combined treatment strategy involving eribulin, anlotinib, and camrelizumab showed promising efficacy and manageable safety in patients with advanced or metastatic RLPS, particularly in those with MLPS.
Keyphrases
  • squamous cell carcinoma
  • small cell lung cancer
  • randomized controlled trial
  • stem cells
  • clinical trial
  • combination therapy
  • phase ii
  • bone marrow
  • replacement therapy
  • robot assisted
  • double blind